Eli Lilly and Company (LLY.MX)
| Previous Close | 16,562.49 |
| Open | 16,135.35 |
| Bid | 15,000.00 x 100 |
| Ask | 16,695.00 x 10000 |
| Day's Range | 16,562.49 - 16,562.49 |
| 52 Week Range | 7,452.75 - 17,062.39 |
| Volume | |
| Avg. Volume | 248 |
| Market Cap | 14.913T |
| Beta (5Y Monthly) | 0.41 |
| PE Ratio (TTM) | 133.33 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 94.17 (0.57%) |
| Ex-Dividend Date | Aug 15, 2024 |
| 1y Target Est | N/A |
- PR Newswire
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease
The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) as well as people with the mild dementia stage of AD, with confirmed amyloid pathology.1, 2 Once-monthly Kisunla is the first and only amyloid plaque-targeting therapy with evidence to suppo
- PR Newswire
Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria
Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens. Antimicrobial resistance (AMR) is one of the top public health and development threats across the global health landscape.
- PR Newswire
Lilly Declares Third-Quarter 2024 Dividend
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2024 of $1.30 per share on outstanding common stock.
